# Kyverna Therapeutics

**Canonical:** https://apis.io/providers/kyverna-therapeutics/  
**Website:** https://kyvernatx.com/  
**APIs profiled:** 0

Kyverna Therapeutics (Nasdaq: KYTX) is a patient-centered, clinical-stage biopharmaceutical company headquartered in Emeryville, California, developing engineered T cell therapies for patients suffering from autoimmune diseases. Kyverna adapts CD19 CAR T-cell therapy — originally developed for B cell cancers — to deeply deplete the B cells that drive autoimmunity, with the goal of durable, drug-free remission. Its lead candidate, mivocabtagene autoleucel (miv-cel, KYV-101), is a fully human CD19 CAR T-cell therapy in Phase 2 development for stiff person syndrome, myasthenia gravis and multiple sclerosis, and in Phase 1/2 development for systemic sclerosis and lupus nephritis in the United States and Germany. The pipeline also includes next-generation autologous and allogeneic CAR T constructs, including KYV-201, built on the company's Ingenui-T rapid manufacturing platform. Kyverna is a biopharmaceutical operating company and publishes no public developer API, SDK, or developer portal; this profile tracks its public web, corporate and investor surface within the API Evangelist network.

## Kin Score — 7.2 / 100 (minimal)

Scored 2026-08-20 under rubric 0.12.0. Trend: flat (+0.0 from 7.2).

| Facet | Score |
|---|---|
| Discoverability | 57.4 |
| Contract Quality | 0.0 |
| Governance | 0.0 |
| Contract Governance | 0.0 |
| Operational Transparency | 0.0 |
| Developer Ergonomics | 1.2 |
| Commercial Clarity | 10.5 |
| Access Clarity | 10.5 |

Regulatory layer — **Health**: 12.5 (matched via tags).

## Agent readiness — 0.0 (human-only)

| Dimension | Value |
|---|---|
| Spec Presence | no |
| Agentic Access | no |
| Reversibility Documented | no |
| MCP Server | no |
| Auth Clarity | no |
| Idempotency | no |
| Error Semantics | no |
| OpenAPI Examples | no |
| Rate Limit Signal | no |
| Event Surface Described | no |
| Agent Skills | no |
| Well Known Catalog | no |
| Consent Identity | no |
| Agent Card | no |
| Dry Run Mode | no |

## Access

Unknown — onboarding: unknown, pricing: unknown, trial: no (confidence: low).

## Security (1)

- **Kyverna Therapeutics Domain Security** — TLSv1.3 · DMARC

## Tags

Company, Biotech Therapeutics, Biotechnology, Cell Therapy, Cart, Autoimmune Disease, Immunology, Neurology, Rheumatology, Clinical Trials, Life Sciences, Public Company

---

Profiled by [API Evangelist](https://apievangelist.com) and published on [APIs.io](https://apis.io/providers/kyverna-therapeutics/). Scores are computed from the provider's own public artifacts under a published rubric.